Compare GSK plc (GSK) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $58.82 (market cap $75.38B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | MDLZ | |
|---|---|---|
Market Cap | $101.34B | $75.38B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $70.75 |
52-Week Low | $36.20 | $51.51 |
Enterprise Value | $121.95B | $95.47B |
Dividend Yield | 3.49% | 3.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Mondelez International (MDLZ) trades at $60.48, up 2.86% with a bearish technical signal despite recent earnings beats. The company reported 2025 revenue of $38.54B with a net income margin of 6.64%, while valuation ratios like P/E of 29.07 suggest premium pricing. Analyst consensus is strongly bullish with a $68.00 price target, supported by innovation in brands like Oreo and Ritz. A dividend of $0.50 per share is scheduled for July 2026, enhancing income appeal amid stable cash flows.
Outlook remains positive due to consistent earnings outperformance and strategic brand initiatives, though risks include margin pressure from input costs and technical bearish indicators. The stock offers growth potential with a margin of safety from analyst targets, but investors should monitor Q2 2026 results on July 28 for volume growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
